Breast cancer
PRINCIPAL INVESTIGATORS
- Amparo García Tejedor
- Albert Antolin Hernandez
- Sonia Pernas Simón
CLINICAL RESEARCHERS
- Juan Miguel Gil Gil
- Catalina Falo Zamora
- Adela Fernández Ortega
- Veronica Luisa Obadia Gil
- María Jesús Pla Farnós
- Bartomeu Fullana Grimalt
- Anna Petit Montserrat
- Sabela Recalde Penabad
- Agostina Stradella Trucco
- Silvia Vázquez Fernández
- Rafael Villanueva Vázquez
POSTDOCTORAL RESEARCHERS
- Leticia Manen Freixa
- Francesca Mateo Gonzalez
PREDOCTORAL RESEARCHERS
- Luis Alfaro Garcia
- Roderic Espin Garcia
- Alexandra Baiges Carrasco
- Arzoo Shabbir
- Lara Ruiz Auladell
SCIENTIFIC SUPPORT
- Santiago Santos Gil
- Miguel Angel Pardo Cea
Cancer
Oncobell
Scientific production
31
PAPERS
Average IF: 10,509
8
LED PAPERS
Average IF: 5,775
13 PUBLICATIONS IN FIRST DECILE
20 PUBLICATIONS IN FIRST QUARTILE
27 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Villacampa,G;Tung,NM;Pernas,S;Paré,L;Bueno Muiño,C;Echavarría,I;López Tarruella,S et al, Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer, Ann. Oncol., 2023;34(9):doi:10.1016/j.annonc.2023.05.012
- Oliveira,M;Falato,C;Cejalvo,JM;Vila,MM;Tolosa,P;Salvador Bo,FJ;Cruz,J et al, Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study, Ann. Oncol., 2023;34(8):670-680, doi:10.1016/j.annonc.2023.05.004
- Patel,PS;Algouneh,A;Krishnan,R;Reynolds,JJ;Nixon,KCJ;Hao,J;Lee,J et al, Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers., Nucleic Acids Res., 2023;51(9):4341-4362, doi:10.1093/nar/gkad172
- Krishnan,R;Lapierre,M;Gautreau,B;Nixon,KCJ;El Ghamrasni,S;Patel,PS;Hao,J et al, RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells, Nucleic Acids Res., 2023;51(19):10484-10505 doi:10.1093/nar/gkad733,
- Ciscar,M;Trinidad,EM;Perez Chacon,G;Alsaleem,M;Jimenez,M;Jimenez Santos,MJ;Perez Montoyo,H et al, RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer., EMBO Mol. Med. 2023;15(4):doi:10.15252/emmm.202216715
Research highlights
PROJECTS
2 Granted competitive projects
12 Ongoing competitive projects
7 Started clinical trials
50 Ongoing clinical trials
INNOVATION
1 Patent
PUBLISHED WORKS
2 Clinical Guidelines
NETWORKS
CIMBA
ENBDC
AGAUR SGR 2017-449
LOBSTERPOT
Selected projects
- LCX21020. Becas de posdoctorado Junior Leader Incoming. FUNDACIÓ “LA CAIXA”. Budget: 297.900€. 2022-2025. PI: GENESTAR PUJANA, MIGUEL ANGEL.
- 2023-595-1. A PHASE 3, OPEN-LABEL, RANDOMIZED, TWO-PART STUDY COMPARING GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND FULVESTRANT TO STANDARD-OF-CARE THERAPIES IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH A CDK4/6 INHIBITOR IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITOR THERAPY (VIKTORIA-1). CELCUITY INC. Budget: 253.918€. 2023- . PI: Stradella Trucco, Agostina.
- 2022-061-1. Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo, con un periodo de preinclusión con un solo grupo, para evaluar la seguridad y la eficacia de un colirio de tiosulfato de sodio (BYON5667) para reducir la toxicidad ocular en pacientes oncológicos tratados con SYD985. BYONDIS B.V.;Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) . Budget: 221.291€. 2022- . PI: Stradella Trucco, Agostina.
- 2021-037-1. SERENA-4: Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, Degradador selectivo del RE, oral) más palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y HER2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada. Astrazeneca Farmacéutica Spain, S.A. Budget: 218.253€. 2021- . PI: OBADIA GIL, VERONICA LUISA.
- FIS22070. CONTRATOS MIGUEL SERVET. Instituto de Salud Carlos III (ISCIII). Budget: 202.500€. 2023-2028. PI: ANTOLIN HERNANDEZ, ALBERT.